Subscribe to RSS
DOI: 10.1055/s-0042-1751835
Design, Synthesis and Biological Evaluation of Imidazole-Substituted/Fused Aryl Derivatives Targeting Tubulin Polymerization as Anticancer Agents
Abstract
The development of new pharmacologically active molecules targeting tubulin polymerization has recently attracted great interest in research groups. In efforts to develop new potent anticancer compounds, imidazole-tethered/fused pharmacologically active aryl derivatives possessing different substitution patterns targeting tubulin polymerization have been rationally designed and synthesized. The target molecules (P1-5 and KG1-5) were synthesized by multistep syntheses involving the reaction of intermediate 2-aminophenyl-tethered imidazoles with appropriate reactants in the presence of p-TsOH under different conditions. The synthesized compounds displayed moderate to good cytotoxicity, comparable to that of colchicine, against four cancer cell lines (MCF-7, MD-MBA-231, A549, and HCT-116). Compounds P2 and P5, with an imidazoloquinoxaline moiety, emerged as potential leads with cytotoxicity profiles against these cell lines similar to colchicine. Compounds P2 and P5 arrested cell division at the G2/M phase and prevented cancerous cell growth through induced apoptosis. These results favored the hypothesis that the compounds might act by binding to the colchicine binding site, which was further confirmed with the help of a tubulin polymerization inhibition assay. The results encourage the further exploration of imidazoloquinoxalines as promising leads that deserve advanced clinical investigation.
Key words
imidazoloquinoxalines - anticancer agents - tubulin - imidazoles - cytotoxicity - cell division - drug designSupporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0042-1751835.
- Supporting Information
Publication History
Received: 18 October 2022
Accepted after revision: 14 December 2022
Article published online:
26 January 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Joshi G, Sharma M, Kalra S, Gavande NS, Singh S, Kumar R. Bioorg. Chem. 2021; 107: 104620
- 2 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. CA: Cancer J. Clin. 2021; 71: 209
- 3 Kumar B, Kumar R, Skvortsova I, Kumar V. Curr. Cancer Drug Targets 2017; 17: 357
- 4 Zich J, Hardwick KG. Trends Biochem. Sci. 2010; 35: 18
- 5a Parker AL, Teo WS, McCarroll JA, Kavallaris M. Int. J. Mol. Sci. 2017; 18: 1434
- 5b Katsetos CD, Herman MM, Mörk SJ. Cell Mot. Cytoskeleton 2003; 55: 77
- 5c Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissiere-Michot F, Maille P, Kheuang L, Coppolani E, Ali A, Bibeau F. Br. J. Cancer 2009; 101: 951
- 6 Pasquier E, Kavallaris M. IUBMB Life 2008; 60: 165
- 7a Yap TA, Sandhu SK, Workman P, De Bono JS. Nat. Rev. Cancer 2010; 10: 514
- 7b Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM. Nat. Rev. Clin. Oncol. 2018; 15: 777
- 7c Wang R, Chen H, Yan W, Zheng M, Zhang T, Zhang Y. Eur. J. Med. Chem. 2020; 190: 112109
- 8 Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Rheumatology 2018; 57 (Suppl. 01) i4
- 9 Wilbur K, Makowsky M. Pharmacotherapy 2004; 24: 1784
- 10 Naaz F, Haider MR, Shafi S, Yar MS. Eur. J. Med. Chem. 2019; 171: 310
- 11a Kaur R, Ranjan Dwivedi A, Kumar B, Kumar V. Anticancer Agents Med. Chem. 2016; 16: 465
- 11b Kumar B, Singh S, Skvortsova I, Kumar V. Curr. Med. Chem. 2017; 24: 4729
- 12a Luca LD. Curr. Med. Chem. 2006; 13: 1
- 12b Sharma A, Kumar V, Kharb R, Kumar S, Chander Sharma P, Pal Pathak D. Curr. Pharm. Des. 2016; 22: 3265
- 12c Saccoliti F, Madia VN, Tudino V, De Leo A, Pescatori L, Messore A, De Vita D, Scipione L, Brun R, Kaiser M. J. Med. Chem. 2019; 62: 1330
- 13 Chen J, Wang Z, Li C.-M, Lu Y, Vaddady PK, Meibohm B, Dalton JT, Miller DD, Li W. J. Med. Chem. 2011; 54 13, 4678
- 14 Courbet A, Bec N, Constant C, Larroque C, Pugniere M, El Messaoudi S, Zghaib Z, Khier S, Deleuze-Masquefa C, Gattacceca F. PLoS One 2017; 12: e0182022
- 15a Ammar YA, El-Sharief MA. M. S, Ghorab MM, Mohamed YA, Ragab A, Abbas SY. Curr. Org. Synth. 2016; 13: 466
- 15b Chen P, Iwanowicz EJ, Norris D, Gu HH, Lin J, Moquin RV, Das J, Wityak J, Spergel SH, De Fex H, Pang S, Pitt S, Shen DR, Schieven GL, Barrish JC. Bioorg. Med. Chem. Lett. 2002; 12: 3153
- 15c De Moliner F, Hulme C. Tetrahedron Lett. 2012; 53: 5787
- 15d Gorle S, Vaikunta Rao L, Chiranjeevi Y, Dhanunjaya Rao AV, Mekala R, Tadiparthi K, Raghunadh A. Synth. Commun. 2022; 52: 218
- 15e Mamedov VA, Kalinin AA. Russ. Chem. Rev. 2014; 83: 820
- 16 Srivastava AR, Bhatia R, Chawla P. Bioorg. Chem. 2019; 89: 102993
- 17a Dinkova-Kostova AT, Talalay P. Mol. Nutr. Food Res. 2008; 52 (Suppl. 01) S128
- 17b Mut-Salud N, Álvarez PJ, Garrido JM, Carrasco E, Aránega A, Rodríguez-Serrano F. Oxid. Med. Cell. Longev. 2016; 2016: 6719534
- 18 Joshi G, Chauhan M, Kumar R, Thakur A, Sharma S, Singh R, Wani AA, Sharon A, Bharatam PV, Kumar R. Org. Chem. Front. 2018; 5: 3526
- 19 Kumar B, Sharma P, Gupta VP, Khullar M, Singh S, Dogra N, Kumar V. Bioorg. Chem. 2018; 78: 130
- 20 Kumar D, Kumar RR, Pathania S, Singh PK, Kalra S, Kumar B. Bioorg. Chem. 2021; 114: 105068
- 21 Beyer CF, Zhang N, Hernandez R, Vitale D, Lucas J, Nguyen T, Discafani C, Ayral-Kaloustian S, Gibbons JJ. Cancer Res. 2008; 68: 2292
- 22 Verma R, Bhatia R, Singh G, Kumar B, Mehan S, Monga V. Bioorg. Chem. 2020; 101: 104010